JP2006525951A - 刺激、炎症および皮膚紅斑の治療および予防のための化粧品および/または薬学的組成物 - Google Patents
刺激、炎症および皮膚紅斑の治療および予防のための化粧品および/または薬学的組成物 Download PDFInfo
- Publication number
- JP2006525951A JP2006525951A JP2005500190A JP2005500190A JP2006525951A JP 2006525951 A JP2006525951 A JP 2006525951A JP 2005500190 A JP2005500190 A JP 2005500190A JP 2005500190 A JP2005500190 A JP 2005500190A JP 2006525951 A JP2006525951 A JP 2006525951A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- dimethylsulfone
- composition
- phase
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 11
- 206010015150 Erythema Diseases 0.000 title claims description 39
- 230000004054 inflammatory process Effects 0.000 title abstract description 9
- 230000007794 irritation Effects 0.000 title abstract description 6
- 206010061218 Inflammation Diseases 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 230000002265 prevention Effects 0.000 title description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 77
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 230000005855 radiation Effects 0.000 claims abstract description 29
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 230000006378 damage Effects 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims abstract description 4
- 230000003612 virological effect Effects 0.000 claims abstract description 4
- 231100000321 erythema Toxicity 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 13
- -1 methyl benzylidene Chemical group 0.000 claims description 8
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003711 photoprotective effect Effects 0.000 claims description 8
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 5
- 239000003410 keratolytic agent Substances 0.000 claims description 5
- 229930002330 retinoic acid Natural products 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000002085 irritant Substances 0.000 claims description 4
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 claims description 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 230000005865 ionizing radiation Effects 0.000 claims description 3
- 229960001679 octinoxate Drugs 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 3
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 claims description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 claims description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims description 2
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 2
- ORWUQAQITKSSRZ-UHFFFAOYSA-N 2-hydroxyethyl 4-[bis[2-(2-hydroxyethoxy)ethyl]amino]benzoate Chemical compound OCCOCCN(CCOCCO)C1=CC=C(C(=O)OCCO)C=C1 ORWUQAQITKSSRZ-UHFFFAOYSA-N 0.000 claims description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010040880 Skin irritation Diseases 0.000 claims description 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002916 adapalene Drugs 0.000 claims description 2
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 2
- 229960005193 avobenzone Drugs 0.000 claims description 2
- 229960002255 azelaic acid Drugs 0.000 claims description 2
- 229960001716 benzalkonium Drugs 0.000 claims description 2
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 claims description 2
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- HEAHZSUCFKFERC-UHFFFAOYSA-N ecamsule Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2=CC(C=C1)=CC=C1C=C1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C HEAHZSUCFKFERC-UHFFFAOYSA-N 0.000 claims description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000655 ensulizole Drugs 0.000 claims description 2
- 229960004881 homosalate Drugs 0.000 claims description 2
- 231100000021 irritant Toxicity 0.000 claims description 2
- 229960003921 octisalate Drugs 0.000 claims description 2
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000601 octocrylene Drugs 0.000 claims description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001173 oxybenzone Drugs 0.000 claims description 2
- 229960003742 phenol Drugs 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001755 resorcinol Drugs 0.000 claims description 2
- 231100000475 skin irritation Toxicity 0.000 claims description 2
- 230000036556 skin irritation Effects 0.000 claims description 2
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000368 sulisobenzone Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims 3
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims 2
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 claims 2
- KKJKXQYVUVWWJP-JLHYYAGUSA-N 4-[(e)-(4,7,7-trimethyl-3-oxo-2-bicyclo[2.2.1]heptanylidene)methyl]benzenesulfonic acid Chemical compound CC1(C)C2CCC1(C)C(=O)\C2=C\C1=CC=C(S(O)(=O)=O)C=C1 KKJKXQYVUVWWJP-JLHYYAGUSA-N 0.000 claims 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229960004319 trichloroacetic acid Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000013043 chemical agent Substances 0.000 abstract description 2
- 239000008406 cosmetic ingredient Substances 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 14
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 7
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 7
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 7
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 7
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 7
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 7
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 7
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 7
- 229960002216 methylparaben Drugs 0.000 description 7
- 239000007764 o/w emulsion Substances 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 229960003415 propylparaben Drugs 0.000 description 7
- 229940100458 steareth-21 Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 3
- 229940117360 ethyl pyruvate Drugs 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229940116333 ethyl lactate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000000985 reflectance spectrum Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Substances OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000009724 venous congestion Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
特に、本発明は、上述した皮膚の徴候を防止および/または治癒するための、局所的使用の薬学的または化粧品組成物の調製におけるジメチルスルホンの使用に関する。
Description
反応性酸素種(ROS)は、炎症プロセスの発生および維持における重要な役割を果たす毒性および高反応性分子である。スーパーオキシドラジカル(O2・)は、単球およびマクロファージ、炎症プロセスに関与した細胞によって生成され、かつそれ自体がプロセスの増幅の役割を果たす。
本発明の確証のために、光保護作用の評価に関する実験と、紫外放射線誘発型の紅斑阻害効果に関する実験を報告した。
光保護の評価と5%ジメチルスルホンに基づいた処方の抗紅斑能力のために、12人の健康なボランティア(実行する実験および手順の性質について事前に通知)が採用された。ボランティア(書面による同意が求められた)は、光II型およびIII型を含む対象から選ばれた。
図2は、未処理部位(対照)とSALDMS 5処方で処理された部位の両方の、時間の関数としての紅斑指数の変化を調査することによって得られた被験者1に関する幾つかの局所的曲線を示す。
製剤1−ローション/溶液
No 内容 % w/w
a
01 ジメチルイソソルビド 40.00
02 ピルビン酸 50.00
03 ジメチルスルホン 10.00
調製の方法:03を01に溶解させ、得られた溶液を02と混合する。
No 内容 % w/w
a
01 ジメチルイソソルビド 40.00
02 トリクロロ酢酸 50.00
03 ジメチルスルホン 10.00
調製の方法:03を01に溶解させ、得られた溶液を02と混合する。
No 内容 % w/w
a
01 ジメチルイソソルビド 20.00
02 グリコール酸 50.00
03 ジメチルスルホン 10.00
04 水 10.00
調製の方法:03+02を01に溶解させ、得られた溶液を04と混合する。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 オクチルメトキシシンナメート 5.00
09 4-メチルベンジリデンカンファー 2.00
フェーズB
10 プロピレングリコール 2.00
11 レチノイン酸 0.025
12 脱塩水 10.00
フェーズC
13 ジメチルスルホン 10.00
14 プロピレングリコール 2.00
15 二ナトリウム EDTA 0.07
16 グリセロール 5.00
17 フェノキシエタノール 1.00
18 メチルパラベン 0.10
19 エチルパラベン 0.10
20 プロピルパラベン 0.10
21 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と撹拌しながら混合して均質溶液を調製し;+45℃まで冷却し;その後にフェーズB)を連続的に撹拌しながら加え、25℃まで冷却する。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 乳酸エチル 5.00
フェーズB
09 プロピレングリコール 2.00
10 アゼライン酸 15.0
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 プロピレングリコール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 乳酸エチル 5.00
フェーズB
09 プロピレングリコール 2.00
10 過酸化ベンゾイル 5.00
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 プロピレングリコール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 レチノイン酸 0.02
フェーズB
09 プロピレングリコール 2.00
10 乳酸 10.00
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 プロピレングリコール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 ピルビン酸エチル 5.00
フェーズB
09 プロピレングリコール 2.00
10 アダパレン 0.20
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 プロピレングリコール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 ピルビン酸エチル 5.00
フェーズB
09 プロピレングリコール 2.00
10 乳酸 10.00
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 プロピレングリコール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
No 内容 % w/w
a
フェーズA
01 Sreareth 2 3.00
02 Steareth 21 2.00
03 Ppg 15 ステアリルエーテル 10.00
04 酢酸トコフェリル 1.00
05 ジャコバ油 2.00
06 Bht 0.01
07 アスコルビルパルミテート 0.10
08 ピルビン酸エチル 5.00
フェーズB
09 プロピレングリコール 2.00
10 乳酸 10.00
11 脱塩水 10.00
フェーズC
12 ジメチルスルホン 10.00
13 メトロニダゾール 2.00
14 二ナトリウム EDTA 0.07
15 グリセロール 5.00
16 フェノキシエタノール 1.00
17 メチルパラベン 0.10
18 エチルパラベン 0.10
19 プロピルパラベン 0.10
20 脱塩水 100 qba
調製の方法:フェーズA)を75℃まで加熱し;フェーズC)を+75℃まで加熱し;フェーズA)をフェーズC)と連続的に撹拌しながら混合して溶液を均質化し;+45℃まで冷却し;その後にフェーズB)と連続的に撹拌しながら混合し、25℃まで冷却した。
X軸−時間(時間)
記号一覧−対照、SALDMS 5、♯RIFI
X軸−SALDMS 5, プラセボ
Claims (10)
- 局所使用のための薬学的または化粧品組成物の調製におけるジメチルスルホンの使用であって、化学的、物理的、細菌性およびウイルス性因子によって誘導された皮膚の炎症を防止および/または治療し、かつ太陽放射線および天然または人工起源の両方を含むA、BおよびC型の紫外放射線によって誘導された損傷を低減させることができる特異的な光保護作用のための使用。
- あらゆる強度および天然の、特に太陽フィルターと結び付いたときの紫外放射線(太陽放射線)、電離放射線、X線、ガンマ線、レーザー光線から選択された物理的因子によって誘導された紅斑を阻害するための請求項1に記載の使用。
- カルボン酸、ジカルボン酸、トリカルボン酸、モノカルボン酸のα-ヒドロキシ酸、ジカルボン酸のα-ヒドロキシ酸、トリカルボン酸のα-ヒドロキシ酸、モノカルボン酸のβ-ヒドロキシ酸、ジカルボン酸のβ-ヒドロキシ酸、トリカルボン酸のβ-ヒドロキシ酸、レゾルシン、フェノール、レチノイン酸、アダパレン、アゼライン酸、サリチル酸、トリクロロ酢酸、過酸化ベンジル、および化粧品および/または薬学分野において使用され得、かつ潜在的な刺激物質として特徴づけられる他の物質から選択された化学物質によって引き起こされた皮膚の炎症を低減させるための請求項1に記載の使用。
- 薬学的有効量のジメチルスルホンを含む局所的使用のための薬学的および/または化粧品組成物。
- 前記ジメチルスルホンが、0.5重量%〜90重量%で存在する請求項4に記載の組成物。
- 前記ジメチルスルホンが、5重量%〜60重量%、好ましくは8重量%〜30重量%で存在する請求項5に記載の組成物。
- 前記組成物が抗紅斑薬または抗刺激薬であり、前記ジメチルスルホンが0.5重量%〜80重量%、好ましくは1重量%〜20重量%の可変量で存在する請求項4ないし6のいずれか1項に記載の組成物。
- 前記組成物が角質溶解剤を含むケミカルピーリングのための処方であり、前記ジメチルスルホンが1重量%〜60重量%で構成された量で存在し、かつ前記角質溶解剤が5重量%〜70重量%で構成された量で存在する請求項4ないし6のいずれか1項に記載の組成物。
- 前記組成物が太陽フィルターを含む処方であって、ジメチルスルホンの量が0.5重量%〜50重量%で構成され、かつ太陽フィルターの量が1重量%〜20重量%で構成される請求項4ないし6のいずれか1項に記載の組成物。
- 前記太陽フィルターが、PABA、ホモサレート、ショウノウ、ベンズアルコニウム、メトサルフェート、ベンゾフェノン-3、フェニルベンズイミダゾールスルホン酸、ブチルメトキシジベンゾイルメタン、テレフタルイリデン ジカンファー スルホン酸、ベンズイリデンカンファースルホン酸、オクトクリレン、オクチルメトキシ桂皮酸塩、ポリアクリルアミドメチル ベンズイリデン、PEG-25 PABA、オクチルサリチル酸塩、オクチルジメチルPABA、イソアミルp-メトキシ桂皮酸塩、ベンゾフェノン-4、3-ベンズイリデンカンファー、4-メチルベンズイリデンカンファー、イソプロピルベンジルサリチル酸塩、オクチルトリアゾネシアから選択される請求項9に記載の組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2003/000340 WO2004105741A1 (en) | 2003-05-30 | 2003-05-30 | Cosmetic and/or pharmaceutical compositions comprising dimthylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006525951A true JP2006525951A (ja) | 2006-11-16 |
Family
ID=33485485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005500190A Pending JP2006525951A (ja) | 2003-05-30 | 2003-05-30 | 刺激、炎症および皮膚紅斑の治療および予防のための化粧品および/または薬学的組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070009451A1 (ja) |
EP (1) | EP1641443B1 (ja) |
JP (1) | JP2006525951A (ja) |
CN (1) | CN1771028A (ja) |
AT (1) | ATE420631T1 (ja) |
AU (1) | AU2003238687B8 (ja) |
CA (1) | CA2525692A1 (ja) |
DE (1) | DE60325904D1 (ja) |
ES (1) | ES2322345T3 (ja) |
HR (1) | HRPK20050965B3 (ja) |
TW (1) | TW200500059A (ja) |
WO (1) | WO2004105741A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008291032A (ja) * | 2008-06-04 | 2008-12-04 | Paoli Ambrosi Gianfranco De | ケミカルピーリングのための処方 |
JP2021521153A (ja) * | 2018-04-09 | 2021-08-26 | ヌーン エスセティック エム.アール リミテッド | ストロンチウムおよびメチルスルホニルメタン(msm)を含む局所製剤ならびに治療方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003238685B2 (en) * | 2003-05-30 | 2009-10-08 | De Paoli Ambrosi, Gianfranco | A formulation for chemical peeling |
ITBS20040068A1 (it) * | 2004-05-24 | 2004-08-24 | Gen Topics Srl | Composizione cosmetica e/o farmaceutica per il trattamento della rosacea |
EP1932524A1 (en) * | 2006-12-13 | 2008-06-18 | Ludwig-Maximilians-Universität München | Pharmaceutical preparations for treating inflammatory diseases |
WO2010047784A1 (en) * | 2008-10-20 | 2010-04-29 | Dow Pharmaceutical Sciences, Inc. | Method for obtaining a stable dispersion of benzoyl peroxide |
ITBS20120093A1 (it) * | 2012-06-04 | 2013-12-05 | Paoli Ambrosi Gianfranco De | Composizione cosmetica e/o farmaceutica per il trattamento dell'infiammazione della cute e delle sindromi correlate |
KR20210122552A (ko) * | 2020-04-01 | 2021-10-12 | (주)아모레퍼시픽 | 피루베이트를 포함하는 비타민 c 산화 방지용 첨가제 조성물 |
WO2023177625A1 (en) * | 2022-03-14 | 2023-09-21 | Blue Hill Technologies Llc | Shelf-stable formulations of benzoyl peroxide and methods of producing same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005301A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone |
WO1994005279A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid |
WO1994005293A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol |
WO1994005272A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide |
EP1230911A1 (en) * | 2001-02-12 | 2002-08-14 | Van Gent Natural Products | cosmetic or pharmaceutical preparation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399093B1 (en) * | 1999-05-19 | 2002-06-04 | Advanced Medical Instruments | Method and composition to treat musculoskeletal disorders |
US6653352B2 (en) * | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6328987B1 (en) * | 2000-11-03 | 2001-12-11 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions containing alpha interferon |
ITBS20040068A1 (it) * | 2004-05-24 | 2004-08-24 | Gen Topics Srl | Composizione cosmetica e/o farmaceutica per il trattamento della rosacea |
-
2003
- 2003-05-30 ES ES03733017T patent/ES2322345T3/es not_active Expired - Lifetime
- 2003-05-30 EP EP03733017A patent/EP1641443B1/en not_active Expired - Lifetime
- 2003-05-30 US US10/557,925 patent/US20070009451A1/en not_active Abandoned
- 2003-05-30 DE DE60325904T patent/DE60325904D1/de not_active Expired - Lifetime
- 2003-05-30 WO PCT/IT2003/000340 patent/WO2004105741A1/en active Application Filing
- 2003-05-30 AU AU2003238687A patent/AU2003238687B8/en not_active Ceased
- 2003-05-30 AT AT03733017T patent/ATE420631T1/de not_active IP Right Cessation
- 2003-05-30 CA CA002525692A patent/CA2525692A1/en not_active Abandoned
- 2003-05-30 JP JP2005500190A patent/JP2006525951A/ja active Pending
- 2003-05-30 CN CNA038265672A patent/CN1771028A/zh active Pending
-
2004
- 2004-05-20 TW TW093114249A patent/TW200500059A/zh unknown
-
2005
- 2005-11-18 HR HR20050965A patent/HRPK20050965B3/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005301A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone |
WO1994005279A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid |
WO1994005293A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol |
WO1994005272A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Skin treatment compositions containing dimethylsulphone and dimethylsulphoxide |
EP1230911A1 (en) * | 2001-02-12 | 2002-08-14 | Van Gent Natural Products | cosmetic or pharmaceutical preparation |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008291032A (ja) * | 2008-06-04 | 2008-12-04 | Paoli Ambrosi Gianfranco De | ケミカルピーリングのための処方 |
JP2021521153A (ja) * | 2018-04-09 | 2021-08-26 | ヌーン エスセティック エム.アール リミテッド | ストロンチウムおよびメチルスルホニルメタン(msm)を含む局所製剤ならびに治療方法 |
US11918666B2 (en) | 2018-04-09 | 2024-03-05 | Noon Aesthetics M.R Ltd. | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment |
Also Published As
Publication number | Publication date |
---|---|
CA2525692A1 (en) | 2004-12-09 |
ES2322345T3 (es) | 2009-06-19 |
US20070009451A1 (en) | 2007-01-11 |
AU2003238687B2 (en) | 2009-07-02 |
DE60325904D1 (de) | 2009-03-05 |
CN1771028A (zh) | 2006-05-10 |
HRPK20050965B3 (en) | 2007-11-30 |
WO2004105741A1 (en) | 2004-12-09 |
HRP20050965A2 (en) | 2006-06-30 |
TW200500059A (en) | 2005-01-01 |
AU2003238687A1 (en) | 2005-01-21 |
ATE420631T1 (de) | 2009-01-15 |
AU2003238687B8 (en) | 2009-08-06 |
EP1641443A1 (en) | 2006-04-05 |
EP1641443B1 (en) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dreher et al. | Effect of topical antioxidants on UV-induced erythema formation when administered after exposure | |
CA2453823C (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
JP2020172555A (ja) | 化粧品及び化粧品を製造するための方法 | |
AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
US20080317792A1 (en) | Composition Based on Mineral Concentrates Derived From Precious Stones | |
EP0629397B1 (fr) | Composition cosmétique ou pharmaceutique anti-radicaux libres pour application topique | |
HRP20050965A2 (en) | Cosmetic and/or pharmaceutical compositions comprising dimethylsulphone for the cure and prevention of irritation, inflammation and cutaneous erythema | |
CN110325246B (zh) | 防晒组合物 | |
US20040057917A1 (en) | Pharmaceutical composition for treatment and /or prevention of a light-dermatosis | |
Montenegro et al. | Protective effect evaluation of free radical scavengers on UVB induced human cutaneous erythema by skin reflectance spectrophotometry | |
JP2019514981A (ja) | 皮膚に対する化粧品または治療用途のためのSaxifraga抽出物 | |
US20220062126A1 (en) | Uv screening and antioxidant composition and use thereof | |
RU2336867C2 (ru) | Композиция для дермального применения, обладающая фотозащитным и антиэритемным действием, содержащая солнечный фильтр и диметилсульфон | |
JP2001322990A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
US20170216350A1 (en) | Compositions of aluminum fluoride and methods of use thereof for the treatment and prevention of actinic keratosis and sun-induced damages | |
KR102047193B1 (ko) | 글루타밀아미도에틸인돌을 활성 성분으로 포함하는 피부 트러블 개선용 외용제 조성물 및 광역학적 치료 조성물 | |
KR101831352B1 (ko) | 인도시아닌 그린-함유 조성물의 광민감제 및 이를 포함하는 조성물 | |
KR20080020853A (ko) | 모로헤이야 추출물 및 이를 함유하는 항염 화장료 조성물 | |
US20160106723A1 (en) | Methods to sense and treat subclinical skin damage | |
JP2001322930A (ja) | 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物 | |
JP2001322930A5 (ja) | ||
MX2008003878A (en) | Composition based on mineral concentrates derived for precious stones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091013 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100215 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100323 |